412 related articles for article (PubMed ID: 11831445)
1. Safety and efficacy of specific immunotherapy with standardized allergenic extracts adsorbed on aluminium hydroxide.
Wüthrich B; Gumowski PL; Fäh J; Hürlimann A; Deluze C; André C; Fadel R; Carat F
J Investig Allergol Clin Immunol; 2001; 11(3):149-56. PubMed ID: 11831445
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis.
Riechelmann H; Schmutzhard J; van der Werf JF; Distler A; Kleinjans HA
Am J Rhinol Allergy; 2010; 24(5):e104-9. PubMed ID: 21244725
[TBL] [Abstract][Full Text] [Related]
4. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
Klimek L; Schendzielorz P; Pinol R; Pfaar O
Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
[TBL] [Abstract][Full Text] [Related]
5. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
[TBL] [Abstract][Full Text] [Related]
6. Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response.
Gallego MT; Iraola V; Himly M; Robinson DS; Badiola C; García-Robaina JC; Briza P; Carnés J
Int Arch Allergy Immunol; 2010; 153(1):61-9. PubMed ID: 20357486
[TBL] [Abstract][Full Text] [Related]
7. Effect of allergen specific immunotherapy (IT) on natural killer cell activity (NK), IgE, IFN-gamma levels and clinical response in patients with allergic rhinitis and asthma.
Sin B; Misirligil Z; Aybay C; Gürbüz L; Imir T
J Investig Allergol Clin Immunol; 1996; 6(6):341-7. PubMed ID: 9015776
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with a mass unit Parietaria judaica extract: a tolerance study with evidence of immunological changes to the major allergen Par j 1.
García Villalmanzo I; Hernández MD; Campos A; Giner AM; Polo F; Cortés C; Basomba A
J Investig Allergol Clin Immunol; 1999; 9(5):321-9. PubMed ID: 10582201
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with an extract of Olea europaea quantified in mass units. Evaluation of the safety and efficacy after one year of treatment.
González P; Florido F; Sáenz de San Pedro B; de la Torre F; Rico P; Martín S
J Investig Allergol Clin Immunol; 2002; 12(4):263-71. PubMed ID: 12926186
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with a Phleum pratense allergen extract induces an immune response to a grass-mix allergen extract.
Martínez-Cócera C; Sastre J; Cimarra M; Quirce S; Fernández-Rivas M; Enríquez-Matas A; Rodríguez-Alvarez M; Martín S
J Investig Allergol Clin Immunol; 2010; 20(1):13-9. PubMed ID: 20232769
[TBL] [Abstract][Full Text] [Related]
11. Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy.
Pipet A; Botturi K; Pinot D; Vervloet D; Magnan A
Respir Med; 2009 Jun; 103(6):800-12. PubMed ID: 19216064
[TBL] [Abstract][Full Text] [Related]
12. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
13. Oral allergy syndrome in patients with airborne pollen allergy treated with specific immunotherapy.
Czarnecka-Operacz M; Jenerowicz D; Silny W
Acta Dermatovenerol Croat; 2008; 16(1):19-24. PubMed ID: 18358104
[TBL] [Abstract][Full Text] [Related]
14. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
Rossi RE; Monasterolo G; Coco G; Operti D
Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
[TBL] [Abstract][Full Text] [Related]
15. One century of allergen-specific immunotherapy for respiratory allergy.
Incorvaia C; Frati F
Immunotherapy; 2011 May; 3(5):629-35. PubMed ID: 21554092
[TBL] [Abstract][Full Text] [Related]
16. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results.
Esch RE; Bush RK; Peden D; Lockey RF
Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081
[TBL] [Abstract][Full Text] [Related]
17. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
18. Safety of inhalant allergen immunotherapy with mass units-standardized extracts.
Nettis E; Giordano D; Pannofino A; Ferrannini A; Tursi A
Clin Exp Allergy; 2002 Dec; 32(12):1745-9. PubMed ID: 12653166
[TBL] [Abstract][Full Text] [Related]
19. [Specific skin reactions induced by individual pollen preparations in hypersensitivity persons].
Paranos S; Petrović S; Vojović I
Srp Arh Celok Lek; 1998; 126(9-10):362-7. PubMed ID: 9863408
[TBL] [Abstract][Full Text] [Related]
20. Rush immunotherapy with sublingual administration of grass allergen extract.
Feliziani V; Marfisi RM; Parmiani S
Allergol Immunopathol (Madr); 1993; 21(5):173-8. PubMed ID: 8160561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
